This Year's Highlights

• Efficacy of SG-1311 demonstrated in orthotopic xenograft studies in glioblastoma multiforme: 100% tumor regression and prolonged survival (published 2005-2007)
• Studies of SG-1311's mechanism of action in glioblastoma multiforme presented at AACR (Q2 2007)
• Completed preliminary assessment of novelty and freedom-to-operate of proprietary technology platform (Q1 2007)

Anticipated Highlights

• Formalize strategic partnership with leading CRO for development of SG-1311 (anticipated Q3 2007)
• Series A financing (anticipated Q1 2008)
• Submission of IND for SG-1311 (anticipated Q4 2008)

Corporate Mission

SanoGene Therapeutics Inc. is an early stage biotechnology company, utilizing innovative RNAi-based technologies to develop biopharmaceutical products for deadly cancers. The Company?s platform technology combines the capabilities of multiple therapeutics into one deliverable product with synergistic effects. This proprietary multi-targeted approach is employed in the development of SanoGene?s lead candidate, SG-1311, for the treatment of glioblastoma multiforme, the most common and deadliest form of brain cancer. Even with today?s gold standard, patients with glioblastoma rarely survive beyond twelve months, creating a drastic and urgent market need worth $500 million dollars annually in the U.S. alone. Early laboratory studies of SG-1311 demonstrate efficacy and safety in animal models, and preclinical testing is currently underway with commencement of human clinical trials targeted for 2009. Founded at the University of Illinois at Chicago, SanoGene brings together scientific and managerial talent, proprietary technology and a scalable business model to deliver the next generation of cancer treatment.